Development of a Postbiotic-Based Orodispersible Film to Prevent Dysbiosis in the Oral Cavity

Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial mic...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioscience (Elite edition) Vol. 17; no. 1; p. 26987
Main Authors Rebelo, Mariana B, Oliveira, Cláudia S, Tavaria, Freni K
Format Journal Article
LanguageEnglish
Published Singapore IMR Press 24.03.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film. Methods: Lactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man–Rogosa–Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted. Results: Postbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line. Conclusions: These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis.
AbstractList Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film. 226V and L26 were cultured in De Man-Rogosa-Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted. Postbiotics demonstrated antimicrobial and antibiofilm activity against following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line. These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis.
Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film. Methods: Lactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man–Rogosa–Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted. Results: Postbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line. Conclusions: These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis.
Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film.BACKGROUNDOral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the ecology of the oralome is more effective in reducing the risk of caries than the complete removal of both harmful and beneficial microorganisms. This work aimed to develop a strategy for preventing dysbiosis in the oral cavity by applying a postbiotic-based orodispersible film.Lactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man-Rogosa-Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted.METHODSLactiplantibacillus plantarum 226V and Lacticaseibacillus paracasei L26 were cultured in De Man-Rogosa-Sharpe (MRS) broth for 48 hours, followed by centrifugation and filtration. Then, the resultant postbiotics were then subjected to various dilutions (10% (v/v), 20% (v/v), 40% (v/v), 60% (v/v) and 100% (v/v)) and co-incubated with Streptococcus mutans. Antimicrobial efficacy, minimal inhibitory concentration, the time required to inhibit S. mutans growth, and antibiofilm properties of the postbiotics were assessed. Subsequently, an orodispersible film comprising polymers and plasticizers, namely Xanthan gum, maltodextrin, and glycerol, was developed as a vehicle for postbiotic delivery. Formulation optimization, physical property evaluation, and cytotoxicity against the TR146 human oral cell line (TR146 cell line) were conducted.Postbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line.RESULTSPostbiotics demonstrated antimicrobial and antibiofilm activity against S. mutans following 24-hour co-incubation. The minimal inhibitory concentration for combined postbiotics administration was 20% (v/v). Remarkably, 79.6 ± 8.15% inhibition of biofilm formation was achieved using 100% (v/v) of the postbiotic derived from L. plantarum 226V. Incorporating postbiotics did not compromise the dissolution time of orodispersible films, all exceeding 20 minutes. Furthermore, solubility improved following postbiotic addition, facilitating ease of handling. Importantly, postbiotic-impregnated orodispersible films were non-cytotoxic when exposed to the TR146 cell line.These findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis.CONCLUSIONSThese findings underscore the potential of orodispersible films loaded with postbiotics as a promising potential intervention for oral dysbiosis.
Author Oliveira, Cláudia S
Tavaria, Freni K
Rebelo, Mariana B
Author_xml – sequence: 1
  givenname: Mariana B
  orcidid: 0009-0002-6228-6545
  surname: Rebelo
  fullname: Rebelo, Mariana B
– sequence: 2
  givenname: Cláudia S
  orcidid: 0000-0002-0113-9528
  surname: Oliveira
  fullname: Oliveira, Cláudia S
– sequence: 3
  givenname: Freni K
  orcidid: 0000-0002-6273-6668
  surname: Tavaria
  fullname: Tavaria, Freni K
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40150984$$D View this record in MEDLINE/PubMed
BookMark eNo9kU1PIzEMhqMVK76Ww_6BVY5wGMiHwyRHKBSQkOCwe0RRJnUgaGbSTaZI_fdELcUXW9bj95XtI7I3phEJ-c3ZueRMy4v59a24NLr9QQ65AdUwxfTergYDB-SklHdW41JxafQ-OQDGFTMaDsnLDX5gn5YDjhNNgTr6nMrUxTRF31y7ggv6lNMiliXmErse6Tz2A50Sfc51sg7drEvFSyw0jnR6w8q7ns7cR5zWv8jP4PqCJ1_5mPyb3_6d3TePT3cPs6vHxgvB2kaFANB60WkjlfO8CyE4FSRTYLyDYILvQgvadzoYAb7lwgCAbtGgcxrkMXnY6i6Se7fLHAeX1za5aDeNlF-ty3WjHm3HDHiUIaAUUC-lg1Ki6jAtjBOSVa3TrdYyp_8rLJMdYvHY927EtCpWci1AM7ax_fOFrroBF9_Gu_NW4GwL-JxKyRi-Ec7s5nt29z35CZ4XihA
Cites_doi 10.7717/peerj.12586.
10.1038/s41598-022-22875-w.
10.1038/s41598-020-78971-2.
10.4103/jisp.jisp_114_21.
10.1007/s40496-014-0041-8
10.33549/physiolres.934967
10.3390/ijms222413475.
10.3390/ph15070844.
10.3390/microorganisms10071326.
10.3390/ph12010032.
10.3389/fmicb.2021.617485.
10.1038/s41598-020-80921-x.
10.4317/medoral.21494.
10.1136/bmj.298.6676.779.
10.1007/s10068-021-01009-4.
10.3390/antibiotics11070880.
10.1016/j.crfs.2022.100413.
10.3390/biom12111640.
10.3389/froh.2022.884683.
10.3390/ma15103591.
10.1177/0895937409335626.
10.3390/md20050335.
10.3389/fvets.2020.602280.
10.3390/nu15020291.
10.3390/ma14174872.
10.1038/s41522-022-00307-x.
10.3390/pharmaceutics14081621.
10.1016/j.ifset.2016.10.010
10.1111/prd.12366.
10.3390/diagnostics11081376.
10.3389/fcimb.2020.00397.
10.3390/biom12050729.
10.3390/pharmaceutics13070998.
10.3390/nu14245296.
10.1371/journal.pone.0263851.
10.1155/2014/952970.
10.1007/s12088-019-00828-8.
10.1038/s41575-021-00440-6.
10.3390/pharmaceutics12070657.
10.3390/microorganisms9020428.
10.15226/sojmid.2013.00114
10.1186/s12934-020-01426-w.
10.3389/fphar.2023.1152588.
10.1007/s12602-023-10045-x.
10.4103/2230-973X.114897.
ContentType Journal Article
Copyright 2025 The Author(s). Published by IMR Press.
Copyright_xml – notice: 2025 The Author(s). Published by IMR Press.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.31083/FBE26987
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-0508
ExternalDocumentID oai_doaj_org_article_b094ce3ffe3245088f552e9e0829a230
40150984
10_31083_FBE26987
Genre Journal Article
GrantInformation_xml – fundername: National Funds from Fundação para a Ciência e a Tecnologia (FCT)
  grantid: UIDB/50016/2020
GroupedDBID ---
3IV
53G
AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
F5P
GROUPED_DOAJ
CGR
CUY
CVF
ECM
EIF
EMOBN
NPM
7X8
ID FETCH-LOGICAL-c2207-5ff447c2b8935ac1bfffa5f30549ca4f9fcbf748cb8f924c712944487e9eaa843
IEDL.DBID DOA
ISSN 1945-0494
1945-0508
IngestDate Wed Aug 27 00:34:01 EDT 2025
Sat Mar 29 10:09:41 EDT 2025
Sat Aug 16 01:30:50 EDT 2025
Tue Jul 01 05:14:15 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords oral dysbiosis
antibiofilm capacity
postbiotics
orodispersible films
Language English
License https://creativecommons.org/licenses/by/4.0
2025 The Author(s). Published by IMR Press.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2207-5ff447c2b8935ac1bfffa5f30549ca4f9fcbf748cb8f924c712944487e9eaa843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0002-6228-6545
0000-0002-6273-6668
0000-0002-0113-9528
OpenAccessLink https://doaj.org/article/b094ce3ffe3245088f552e9e0829a230
PMID 40150984
PQID 3182480084
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_b094ce3ffe3245088f552e9e0829a230
proquest_miscellaneous_3182480084
pubmed_primary_40150984
crossref_primary_10_31083_FBE26987
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-03-24
PublicationDateYYYYMMDD 2025-03-24
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-24
  day: 24
PublicationDecade 2020
PublicationPlace Singapore
PublicationPlace_xml – name: Singapore
PublicationTitle Frontiers in bioscience (Elite edition)
PublicationTitleAlternate Front Biosci (Elite Ed)
PublicationYear 2025
Publisher IMR Press
Publisher_xml – name: IMR Press
References ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref23
ref45
ref26
ref25
ref20
ref42
ref41
ref22
ref44
ref21
ref43
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
References_xml – ident: ref17
  doi: 10.7717/peerj.12586.
– ident: ref22
  doi: 10.1038/s41598-022-22875-w.
– ident: ref7
  doi: 10.1038/s41598-020-78971-2.
– ident: ref27
  doi: 10.4103/jisp.jisp_114_21.
– ident: ref6
  doi: 10.1007/s40496-014-0041-8
– ident: ref11
  doi: 10.33549/physiolres.934967
– ident: ref14
  doi: 10.3390/ijms222413475.
– ident: ref32
  doi: 10.3390/ph15070844.
– ident: ref5
  doi: 10.3390/microorganisms10071326.
– ident: ref38
  doi: 10.3390/ph12010032.
– ident: ref42
  doi: 10.3389/fmicb.2021.617485.
– ident: ref12
  doi: 10.1038/s41598-020-80921-x.
– ident: ref26
  doi: 10.4317/medoral.21494.
– ident: ref3
  doi: 10.1136/bmj.298.6676.779.
– ident: ref33
  doi: 10.1007/s10068-021-01009-4.
– ident: ref1
  doi: 10.3390/antibiotics11070880.
– ident: ref20
  doi: 10.1016/j.crfs.2022.100413.
– ident: ref19
  doi: 10.3390/biom12111640.
– ident: ref30
  doi: 10.3389/froh.2022.884683.
– ident: ref37
  doi: 10.3390/ma15103591.
– ident: ref13
  doi: 10.1177/0895937409335626.
– ident: ref41
  doi: 10.3390/md20050335.
– ident: ref21
  doi: 10.3389/fvets.2020.602280.
– ident: ref24
  doi: 10.3390/nu15020291.
– ident: ref29
  doi: 10.3390/ma14174872.
– ident: ref4
  doi: 10.1038/s41522-022-00307-x.
– ident: ref31
  doi: 10.3390/pharmaceutics14081621.
– ident: ref40
  doi: 10.1016/j.ifset.2016.10.010
– ident: ref10
  doi: 10.1111/prd.12366.
– ident: ref2
  doi: 10.3390/diagnostics11081376.
– ident: ref35
  doi: 10.3389/fcimb.2020.00397.
– ident: ref23
  doi: 10.3390/biom12050729.
– ident: ref28
  doi: 10.3390/pharmaceutics13070998.
– ident: ref18
  doi: 10.3390/nu14245296.
– ident: ref39
  doi: 10.1371/journal.pone.0263851.
– ident: ref43
  doi: 10.1155/2014/952970.
– ident: ref8
  doi: 10.1007/s12088-019-00828-8.
– ident: ref15
  doi: 10.1038/s41575-021-00440-6.
– ident: ref45
  doi: 10.3390/pharmaceutics12070657.
– ident: ref9
  doi: 10.3390/microorganisms9020428.
– ident: ref36
  doi: 10.15226/sojmid.2013.00114
– ident: ref25
  doi: 10.1186/s12934-020-01426-w.
– ident: ref34
  doi: 10.3389/fphar.2023.1152588.
– ident: ref16
  doi: 10.1007/s12602-023-10045-x.
– ident: ref44
  doi: 10.4103/2230-973X.114897.
SSID ssj0000651398
Score 2.3572788
Snippet Background: Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that...
Oral diseases affect over three billion peopleand are among the most commonly observed infections worldwide. Recent studies have shown that controlling the...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 26987
SubjectTerms Anti-Bacterial Agents - pharmacology
antibiofilm capacity
Biofilms
Cell Line
Dysbiosis - prevention & control
Humans
Hydrogen-Ion Concentration
Lactobacillaceae - physiology
Microbial Viability
Mouth - microbiology
oral dysbiosis
orodispersible films
postbiotics
Streptococcus - physiology
streptococcus mutans
Title Development of a Postbiotic-Based Orodispersible Film to Prevent Dysbiosis in the Oral Cavity
URI https://www.ncbi.nlm.nih.gov/pubmed/40150984
https://www.proquest.com/docview/3182480084
https://doaj.org/article/b094ce3ffe3245088f552e9e0829a230
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSwMxEA7Sg3gR39YXUbyGbrNJNzna2lIE9WKhF1mSNAMLdVfc9uC_d7K7LXsRL16XgQkzycw3m8k3hNw7RGyca8G49sCElzEzXHqWcOUicNHAQdXl-zKYzsTTXM5bo75CT1hND1wbrmex_nA-BvCY-gOaACm51z68CTWIn0P0xZzXKqbqGCwR2lTv4LSQLJCg1LRCiGZU3JsMx3ygQxtdKxlVnP2_A80q4UwOyH6DFOlDvcJDsuPzI7L73NyFH5P3Vr8PLYAaGgbv2qxAeTbE5LSgrxgds0AFjvt-6ekkW37QVUEb2ib6-F2ieJmVNMspAkGUR4UjE8ZJnJDZZPw2mrJmWAJznEcJkwBCJI5bBCDSuL4FACMBj7PQzgjQ4CwkQjmrAGsul2CiF1ibJWhLY5SIT0knL3J_Tih6ySslbRTrhZAuQoii1MLz_iCyPJLQJXcbq6WfNSdGirVEZdp0Y9ouGQZ7bgUCjXX1AZ2bNs5N_3Jul9xuvJHitg93GSb3xbpEZYoLFaYBdMlZ7aatKhH-4mglLv5jCZdkj4eRv1HMuLgindXX2l8jDlnZm2rL_QB63Nap
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+Postbiotic-Based+Orodispersible+Film+to+Prevent+Dysbiosis+in+the+Oral+Cavity&rft.jtitle=Frontiers+in+bioscience+%28Elite+edition%29&rft.au=Mariana+B+Rebelo&rft.au=Cl%C3%A1udia+S+Oliveira&rft.au=Freni+K+Tavaria&rft.date=2025-03-24&rft.pub=IMR+Press&rft.issn=1945-0494&rft.volume=17&rft.issue=1&rft.spage=26987&rft_id=info:doi/10.31083%2FFBE26987&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b094ce3ffe3245088f552e9e0829a230
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1945-0494&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1945-0494&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1945-0494&client=summon